Circassia releases Phase II cat allergy vaccine trial results
Earlier, the study was initiated as a randomized double-blind Phase II trial in 202 cat allergy patients, in which those who received four doses of Circassia’s T-cell vaccine
Amgen has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for Repatha (evolocumab) supporting its broader use prior to a first heart attack or stroke.